Journal
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Volume 40, Issue 6, Pages 229-234Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.urolonc.2020.08.001
Keywords
Penile cancer; Penile squamous cell carcinoma; Relapsed; Refractory; Chemotherapy; Immune therapy
Categories
Funding
- ASCO Conquer Cancer Foundation Young Investigator Award
Ask authors/readers for more resources
This review discusses the relapse of penile cancer patients after cisplatin-based chemotherapy and explores the available chemotherapy and targeted therapies for salvage second line systemic treatment. It also summarizes the ongoing interventional clinical trials using immune and human papilloma virus-based therapies.
Most patients with advanced penile cancer will have relapsed disease after cisplatin-based combination chemotherapy. Unfortunately, these patients have dismal outcomes with salvage chemotherapy, surgery, or radiation. In this review we will discuss the available chemotherapy and targeted therapies for salvage second line systemic treatment for patients with penile cancer. We will also summarize the ongoing interventional clinical trials using immune and human papilloma virus-based therapies. (c) 2020 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
